PL363288A1 - Połączenie obejmujące inhibitor przekazywania sygnału i pochodną epotylonową - Google Patents

Połączenie obejmujące inhibitor przekazywania sygnału i pochodną epotylonową

Info

Publication number
PL363288A1
PL363288A1 PL02363288A PL36328802A PL363288A1 PL 363288 A1 PL363288 A1 PL 363288A1 PL 02363288 A PL02363288 A PL 02363288A PL 36328802 A PL36328802 A PL 36328802A PL 363288 A1 PL363288 A1 PL 363288A1
Authority
PL
Poland
Prior art keywords
combination
signal transduction
transduction inhibitor
epothilone derivative
derivative
Prior art date
Application number
PL02363288A
Other languages
English (en)
Other versions
PL207197B1 (pl
Inventor
Ralf Brandt
Elisabeth Buchdunger
Carl-Henrik Heldin
Arne Östman
Kristian Pietras
Terence O'reilly
John David Rothermel
Peter Traxler
Markus Wartmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0104840.4A external-priority patent/GB0104840D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL363288A1 publication Critical patent/PL363288A1/pl
Publication of PL207197B1 publication Critical patent/PL207197B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL363288A 2001-02-27 2002-02-26 Połączenie obejmujące inhibitor przekazywania sygnału i pochodną epotylonową, kompozycja farmaceutyczna zawierająca to połączenie oraz zastosowanie połączenia PL207197B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0104840.4A GB0104840D0 (en) 2001-02-27 2001-02-27 Use of organic compounds
US33904001P 2001-10-30 2001-10-30
PCT/EP2002/002049 WO2002067941A2 (en) 2001-02-27 2002-02-26 Combination comprising a signal transduction inhibitor and an epothilone derivative

Publications (2)

Publication Number Publication Date
PL363288A1 true PL363288A1 (pl) 2004-11-15
PL207197B1 PL207197B1 (pl) 2010-11-30

Family

ID=26245767

Family Applications (1)

Application Number Title Priority Date Filing Date
PL363288A PL207197B1 (pl) 2001-02-27 2002-02-26 Połączenie obejmujące inhibitor przekazywania sygnału i pochodną epotylonową, kompozycja farmaceutyczna zawierająca to połączenie oraz zastosowanie połączenia

Country Status (22)

Country Link
US (1) US7723339B2 (pl)
EP (1) EP1385522B1 (pl)
JP (1) JP4499359B2 (pl)
KR (1) KR100848197B1 (pl)
CN (1) CN1511036B (pl)
AT (1) ATE434438T1 (pl)
AU (1) AU2002308218B2 (pl)
BR (1) BR0207649A (pl)
CA (1) CA2439268C (pl)
CY (1) CY1109347T1 (pl)
DE (1) DE60232719D1 (pl)
DK (1) DK1385522T3 (pl)
ES (1) ES2326264T3 (pl)
IL (2) IL157466A0 (pl)
MX (1) MXPA03007729A (pl)
NO (1) NO325416B1 (pl)
NZ (1) NZ527764A (pl)
PL (1) PL207197B1 (pl)
PT (1) PT1385522E (pl)
RU (1) RU2313345C2 (pl)
SK (1) SK287489B6 (pl)
WO (1) WO2002067941A2 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
HRP20030831B1 (en) 2001-03-14 2012-08-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
MXPA03010401A (es) * 2001-05-16 2004-03-09 Novartis Ag Combinacion que comprende n-[5-[4- (4-metil- piperazino-metil) -benzoilamido] -2-metilfenil] -4-(3-piridil)-2 -pirimidin-amina, y un agente quimioterapeutico.
EP1704863A3 (en) * 2001-05-16 2010-11-24 Novartis AG Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent
JP2005507424A (ja) * 2001-10-29 2005-03-17 ノバルティス アクチエンゲゼルシャフト 固形腫瘍の処置における７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体の使用
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DE60310916T2 (de) 2002-08-23 2007-11-15 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
AU2006336468B2 (en) 2005-02-11 2012-04-12 University Of Southern California Method of expressing proteins with disulfide bridges
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
MX2012013100A (es) 2010-05-18 2013-01-22 Cerulean Pharma Inc Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
TW225528B (pl) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
CN1100778C (zh) * 1995-07-06 2003-02-05 诺瓦蒂斯有限公司 吡咯并嘧啶及其制备方法
DE59712968D1 (de) 1996-11-18 2008-10-30 Biotechnolog Forschung Gmbh Epothilone E und F
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
WO2000000485A1 (de) * 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
EE200100422A (et) * 1999-02-11 2002-12-16 Schering Aktiengesellschaft Epotilooni derivaadid, nende valmistamismeetod jafarmatseutiline kasutamine
DE19908760A1 (de) * 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung

Also Published As

Publication number Publication date
NO20033769L (no) 2003-08-25
DK1385522T3 (da) 2009-10-12
WO2002067941A3 (en) 2003-11-20
NZ527764A (en) 2006-01-27
CA2439268A1 (en) 2002-09-06
WO2002067941A8 (en) 2003-12-18
EP1385522A2 (en) 2004-02-04
CN1511036A (zh) 2004-07-07
MXPA03007729A (es) 2003-12-04
IL157466A (en) 2012-04-30
JP2004527493A (ja) 2004-09-09
AU2002308218B2 (en) 2005-11-10
IL157466A0 (en) 2004-03-28
SK10712003A3 (sk) 2004-02-03
ATE434438T1 (de) 2009-07-15
RU2313345C2 (ru) 2007-12-27
DE60232719D1 (de) 2009-08-06
BR0207649A (pt) 2004-03-09
ES2326264T3 (es) 2009-10-06
CN1511036B (zh) 2010-05-05
PT1385522E (pt) 2009-09-04
KR20040025900A (ko) 2004-03-26
US7723339B2 (en) 2010-05-25
NO325416B1 (no) 2008-04-21
WO2002067941A2 (en) 2002-09-06
HK1062266A1 (en) 2004-10-29
US20040132754A1 (en) 2004-07-08
JP4499359B2 (ja) 2010-07-07
CY1109347T1 (el) 2014-07-02
SK287489B6 (sk) 2010-11-08
KR100848197B1 (ko) 2008-07-24
CA2439268C (en) 2010-01-19
RU2003127392A (ru) 2005-03-27
PL207197B1 (pl) 2010-11-30
NO20033769D0 (no) 2003-08-25
EP1385522B1 (en) 2009-06-24

Similar Documents

Publication Publication Date Title
CY1109347T1 (el) Συνδυασμος που αποτελειται απο εναν αναστολεα μεταλλαγης σηματος και ενα παραγωγο εποθιλονης
PL371466A1 (pl) Stenty pokrywane N-{5-[4-(4-metylopiperazynometylo)-benzoiloamido]-2-metylofenylo}-4-(3-pirydylo)-2-pirymidynoamin�
AU2003259521A8 (en) Combination of a) n-{5-(4-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
CY2022009I2 (el) Διυδροναφθυριδινες και σχετικες ενωσεις χρησιμες ως αναστολεις κινασης για τη θεραπεια πολλαπλασιαστικων ασθενειων
NO20022864L (no) Aminotiazol inhibitorer av syklin uavhengig kinase
NO20034490L (no) Fremgangsmåte for sammensetting av absorberende gjenstand til personlig pleie
NO20034713D0 (no) Kombinasjon omfattende N-{5-[4-(4-metylpiperazinometyl)- benzoylamido]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidinamin og et kjemoterapeutiskmiddel
NO20023319D0 (no) Substituerte glutarimider og deres anvendelse som inhibitorer av IL-12-produksjonen
EE200300041A (et) Tsükliin-sõltuvate kinaaside N-[5-[[[5-alküül-2-oksasolüül]metüül]tio]-2-tiasolüül]karboksamiidinhibiitorid
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
DE60308337D1 (de) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide zur behandlung von ang-ii vermittelt krankheiten
DE60332862D1 (de) 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
SG127737A1 (en) Piperidine and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
ECSP066656A (es) COMBINACIÓN DE (a) N-{5-[4-(4-METIL-PIPERAZINO-METIL)-BENZOILAMIDO]2-METILFENIL}-4-(3-PIRIDIL)-2-PIRIMIDINA-AMINA Y (b) POR LO MENOS UN INHIBIDOR DE HIPUSINACIÓN Y EL USO DE LA MISMA
NO20023785L (no) Vanndispergerbar formulering av paroxetin
NO20034124L (no) Sammensetning av et taxan og en cyclinavhengig kinaseinhibitor
HK1095273A (en) Combination of (a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2methylphenyl]-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the use thereof
ATE348615T1 (de) 2-(4-(2-hydroxymethyl-phenylamino)-piperidin-1- yl)-n-(9h-carbazol-3-yl) - acetamid derivate und verwandte verbindungen als neuropeptide y5 (npy5) liganden zur behandlung von fettleibigkeit
HK1071316A (en) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents
EE200000638A (et) 1-(6-kloronaft-2-üülsulfonüül)-4-[4-(4-püridüül)bensoüül]-piperasiini vähendatud osakesesuurusega vorm
DE60204791D1 (de) Synthese von 4-(piperidyl) (2-pyridyl)methanon-(e)-o-methyloxim und seinen salzen
ATE476183T1 (de) Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer
EP1337257A4 (en) USE OF NEUROPEPTIDE Y ANTAGONISTS IN THE TREATMENT OF ALCOHOLISM
ZA200305379B (en) Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase.
SI1436282T1 (en) Synthesis of 4-(piperidyl) (2-pyridyl)methanone-(e)-o-methyloxime and its salts

Legal Events

Date Code Title Description
RECP Rectifications of patent specification
LAPS Decisions on the lapse of the protection rights

Effective date: 20140226